Article: EVerT2-needling versus non-surgical debridement for the treatment of verrucae: study protocol for a single-centre randomised controlled trial

Introduction: Verrucae are extremely common, and are experienced by most people at some time during their lives. Although most verrucae will spontaneously disappear without treatment, many patients seek treatment, often because they have persisted for many years, are unsightly or painful or prevent them from doing sports or other activities. There are many different treatments available; including the Falknor's needling procedure. To date, there has only been one small trial evaluating the clinical effectiveness of this treatment and no health economic analysis has been undertaken. The Effective Verruca Treatments (EVerT2) trial aims to evaluate the clinical and cost-effectiveness of the needling procedure for the treatment of verrucae.

Methods And Analysis: This single-centre randomised controlled trial will recruit 58 participants (aged 18 years and over with a plantar verruca) from Salford Podiatry Clinic patient lists and the surrounding area. If the participant presents with multiple verrucae, an 'index' verruca (largest and thickest lesion) will be identified and patients will be randomised 1:1 to the intervention group to receive the needling treatment or the control group to have the callus overlying the verruca debrided. The primary outcome is complete clearance of the index verruca at 12 weeks after randomisation. Secondary outcomes include clearance and recurrence of the treated verruca, clearance of all verrucae, number of verrucae remaining, change in size of the index verruca, pain, and participant satisfaction. A cost-effectiveness analysis of the needling versus callus debridement will be carried out from the perspective of health services over a time horizon of 12 weeks.

Ethics And Dissemination: Ethical approval has been obtained from the University of Salford, Department of Health Sciences Ethical Approval Committee (HSCR15/24) and the University of York, Department of Health Sciences Research Governance Committee (HSRGC/2014/98/B). Findings will be disseminated through publication and conference presentations.

Trial Registration Number: ISRCTN16429440.

Citing Articles

Characterization of type-specific HPV prevalence in a population of persistent cutaneous warts in Flanders, Belgium.

Redzic N, Pereira A, Menon S, Bogers J, Coppens A, Kehoe K Sci Rep. 2023; 13(1):17492.

PMID: 37840107 PMC: 10577142. DOI: 10.1038/s41598-023-44154-y.

Efficacy of AV2-Salicylic acid combination therapy for cutaneous warts: Study protocol for a single-center randomized controlled trial.

Redzic N, Benoy I, Broeck D, Bogers J Contemp Clin Trials Commun. 2020; 17:100534.

PMID: 32211559 PMC: 7083756. DOI: 10.1016/j.conctc.2020.100534.

Assessment of cardiac resynchronisation therapy in patients with wide QRS and non-specific intraventricular conduction delay: rationale and design of the multicentre randomised NICD-CRT study.

Eschalier R, Ploux S, Pereira B, Clementy N, Da Costa A, Defaye P BMJ Open. 2016; 6(11):e012383.

PMID: 27836874 PMC: 5129079. DOI: 10.1136/bmjopen-2016-012383.

References

1.

REA J, NEWHOUSE M, Halil T . Skin disease in Lambeth. A community study of prevalence and use of medical care. Br J Prev Soc Med. 1976; 30(2):107-14. PMC: 478948. DOI: 10.1136/jech.30.2.107. View

2.

Sterling J, Handfield-Jones S, Hudson P . Guidelines for the management of cutaneous warts. Br J Dermatol. 2001; 144(1):4-11. DOI: 10.1046/j.1365-2133.2001.04066.x. View

3.

JOHNSON M, Roberts J . Skin conditions and related need for medical care among persons 1-74 years. United States, 1971-1974. Vital Health Stat 11. 1978; (212):i-v, 1-72. View

4.

Kwok C, Gibbs S, Bennett C, Holland R, Abbott R . Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012; (9):CD001781. PMC: 8101088. DOI: 10.1002/14651858.CD001781.pub3. View

5.

Falknor G . Needling--a new technique in verruca therapy. J Am Podiatry Assoc. 1969; 59(2):51-2. DOI: 10.7547/87507315-59-2-51. View

6.

MASSING A, Epstein W . Natural history of warts. A two-year study. Arch Dermatol. 1963; 87:306-10. DOI: 10.1001/archderm.1963.01590150022004. View

7.

Cockayne S, Curran M, Denby G, Hashmi F, Hewitt C, Hicks K . EVerT: cryotherapy versus salicylic acid for the treatment of verrucae--a randomised controlled trial. Health Technol Assess. 2011; 15(32):1-170. DOI: 10.3310/hta15320. View

8.

Beliaeva T . [The population incidence of warts]. Vestn Dermatol Venerol. 1990; (2):55-8. View

9.

Longhurst B, Bristow I . The Treatment of Verrucae Pedis Using Falknor's Needling Method: A Review of 46 Cases. J Clin Med. 2015; 2(2):13-21. PMC: 4470114. DOI: 10.3390/jcm2020013. View

10.

Cunningham D, Brimage J, Naraghi R, Bower V . Needling versus liquid nitrogen cryotherapy for the treatment of pedal warts a randomized controlled pilot study. J Am Podiatr Med Assoc. 2014; 104(4):394-401. DOI: 10.7547/0003-0538-104.4.394. View

11.

Liebl H, Kloth L . Skin cell proliferation stimulated by microneedles. J Am Coll Clin Wound Spec. 2014; 4(1):2-6. PMC: 3921236. DOI: 10.1016/j.jccw.2012.11.001. View

12.

Gibbs S, Harvey I . Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2006; (3):CD001781. DOI: 10.1002/14651858.CD001781.pub2. View

EVerT2-needling Versus Non-surgical Debridement for the Treatment of Verrucae: Study Protocol for a Single-centre Randomised Controlled Trial